Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 195

1.

A seven-marker signature and clinical outcome in malignant melanoma: a large-scale tissue-microarray study with two independent patient cohorts.

Meyer S, Fuchs TJ, Bosserhoff AK, Hofstädter F, Pauer A, Roth V, Buhmann JM, Moll I, Anagnostou N, Brandner JM, Ikenberg K, Moch H, Landthaler M, Vogt T, Wild PJ.

PLoS One. 2012;7(6):e38222. doi: 10.1371/journal.pone.0038222. Epub 2012 Jun 7.

2.

Methylthioadenosine phosphorylase represents a predictive marker for response to adjuvant interferon therapy in patients with malignant melanoma.

Meyer S, Wild PJ, Vogt T, Bataille F, Ehret C, Gantner S, Landthaler M, Klinkhammer-Schalke M, Hofstaedter F, Bosserhoff AK.

Exp Dermatol. 2010 Aug;19(8):e251-7. doi: 10.1111/j.1600-0625.2010.01072.x.

3.

Prognostic significance of cytoplasmic p27 expression in human melanoma.

Chen G, Cheng Y, Zhang Z, Martinka M, Li G.

Cancer Epidemiol Biomarkers Prev. 2011 Oct;20(10):2212-21. doi: 10.1158/1055-9965.EPI-11-0472. Epub 2011 Aug 9.

4.

E- to N-cadherin switch in melanoma is associated with decreased expression of phosphatase and tensin homolog and cancer progression.

Lade-Keller J, Riber-Hansen R, Guldberg P, Schmidt H, Hamilton-Dutoit SJ, Steiniche T.

Br J Dermatol. 2013 Sep;169(3):618-28. doi: 10.1111/bjd.12426.

PMID:
23662813
5.

CEACAM1 expression in cutaneous malignant melanoma predicts the development of metastatic disease.

Thies A, Moll I, Berger J, Wagener C, Brümmer J, Schulze HJ, Brunner G, Schumacher U.

J Clin Oncol. 2002 May 15;20(10):2530-6.

PMID:
12011132
6.

High MCM3 expression is an independent biomarker of poor prognosis and correlates with reduced RBM3 expression in a prospective cohort of malignant melanoma.

Nodin B, Fridberg M, Jonsson L, Bergman J, Uhlén M, Jirström K.

Diagn Pathol. 2012 Jul 17;7:82. doi: 10.1186/1746-1596-7-82.

7.

Bax expression measured by AQUAnalysis is an independent prognostic marker in oral squamous cell carcinoma.

Bose P, Klimowicz AC, Kornaga E, Petrillo SK, Matthews TW, Chandarana S, Magliocco AM, Brockton NT, Dort JC.

BMC Cancer. 2012 Aug 1;12:332. doi: 10.1186/1471-2407-12-332.

8.

Immunohistochemical analysis of molecular drivers in melanoma identifies p16 as an independent prognostic biomarker.

Lade-Keller J, Riber-Hansen R, Guldberg P, Schmidt H, Hamilton-Dutoit SJ, Steiniche T.

J Clin Pathol. 2014 Jun;67(6):520-8. doi: 10.1136/jclinpath-2013-202127. Epub 2014 Mar 7.

PMID:
24607493
9.

Gene expression profiling of primary cutaneous melanoma and clinical outcome.

Winnepenninckx V, Lazar V, Michiels S, Dessen P, Stas M, Alonso SR, Avril MF, Ortiz Romero PL, Robert T, Balacescu O, Eggermont AM, Lenoir G, Sarasin A, Tursz T, van den Oord JJ, Spatz A; Melanoma Group of the European Organization for Research and Treatment of Cancer.

J Natl Cancer Inst. 2006 Apr 5;98(7):472-82.

10.

Systematic antibody generation and validation via tissue microarray technology leading to identification of a novel protein prognostic panel in breast cancer.

O Leary PC, Penny SA, Dolan RT, Kelly CM, Madden SF, Rexhepaj E, Brennan DJ, McCann AH, Pontén F, Uhlén M, Zagozdzon R, Duffy MJ, Kell MR, Jirström K, Gallagher WM.

BMC Cancer. 2013 Apr 2;13:175. doi: 10.1186/1471-2407-13-175.

11.

Tissue microarray analysis of methylthioadenosine phosphorylase protein expression in melanocytic skin tumors.

Wild PJ, Meyer S, Bataille F, Woenckhaus M, Ameres M, Vogt T, Landthaler M, Pauer A, Klinkhammer-Schalke M, Hofstaedter F, Bosserhoff AK.

Arch Dermatol. 2006 Apr;142(4):471-6.

PMID:
16618867
12.

nm23 as a prognostic marker in primary cutaneous melanoma: evaluation using tissue microarray in a patient group with long-term follow-up.

Pacifico MD, Grover R, Richman PI, Buffa F, Daley FM, Wilson GD.

Melanoma Res. 2005 Oct;15(5):435-40.

PMID:
16179871
13.

Prognostic value of galectin-3 in primary cutaneous melanoma.

Buljan M, Šitum M, Tomas D, Milošević M, Krušlin B.

J Eur Acad Dermatol Venereol. 2011 Oct;25(10):1174-81. doi: 10.1111/j.1468-3083.2010.03943.x. Epub 2010 Dec 22.

PMID:
21175876
14.

Novel role for RGS1 in melanoma progression.

Rangel J, Nosrati M, Leong SP, Haqq C, Miller JR 3rd, Sagebiel RW, Kashani-Sabet M.

Am J Surg Pathol. 2008 Aug;32(8):1207-12. doi: 10.1097/PAS.0b013e31816fd53c.

PMID:
18580492
15.

Melanoma prognostic model using tissue microarrays and genetic algorithms.

Gould Rothberg BE, Berger AJ, Molinaro AM, Subtil A, Krauthammer MO, Camp RL, Bradley WR, Ariyan S, Kluger HM, Rimm DL.

J Clin Oncol. 2009 Dec 1;27(34):5772-80. doi: 10.1200/JCO.2009.22.8239. Epub 2009 Nov 2.

16.

Cancer-testis antigen expression in primary cutaneous melanoma has independent prognostic value comparable to that of Breslow thickness, ulceration and mitotic rate.

Svobodová S, Browning J, MacGregor D, Pollara G, Scolyer RA, Murali R, Thompson JF, Deb S, Azad A, Davis ID, Cebon JS.

Eur J Cancer. 2011 Feb;47(3):460-9. doi: 10.1016/j.ejca.2010.09.042. Epub 2010 Nov 4.

PMID:
21115342
17.

Prognostic significance of nuclear receptor coactivator-3 overexpression in primary cutaneous melanoma.

Rangel J, Torabian S, Shaikh L, Nosrati M, Baehner FL, Haqq C, Leong SP, Miller JR 3rd, Sagebiel RW, Kashani-Sabet M.

J Clin Oncol. 2006 Oct 1;24(28):4565-9.

18.

Low RBM3 protein expression correlates with tumour progression and poor prognosis in malignant melanoma: an analysis of 215 cases from the Malmö Diet and Cancer Study.

Jonsson L, Bergman J, Nodin B, Manjer J, Pontén F, Uhlén M, Jirström K.

J Transl Med. 2011 Jul 21;9:114. doi: 10.1186/1479-5876-9-114.

19.

Ulceration as a predictive marker for response to adjuvant interferon therapy in melanoma.

McMasters KM, Edwards MJ, Ross MI, Reintgen DS, Martin RC 2nd, Urist MM, Noyes RD, Sussman JJ, Stromberg AJ, Scoggins CR.

Ann Surg. 2010 Sep;252(3):460-5; discussion 465-6. doi: 10.1097/SLA.0b013e3181f20bb1.

PMID:
20739846
20.

Highly sensitive multivariable assay detection of melanocytic differentiation antigens and angiogenesis biomarkers in sentinel lymph nodes with melanoma micrometastases.

Vitoux D, Mourah S, Kerob D, Verola O, Basset-Seguin N, Baccard M, Schartz N, Ollivaud L, Archimbaud A, Servant JM, Revol M, Toubert ME, Podgorniak MP, Plassa F, Porcher R, Lebbé C.

Arch Dermatol. 2009 Oct;145(10):1105-13. doi: 10.1001/archdermatol.2009.209.

PMID:
19841396
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk